Introduction {#s1}
============

Organogenesis relies upon the coordinated regulation of precisely defined patterns of cell movement. Multiple precursor cell populations must convene at the appropriate location and organize into the correct configuration in order to insure proper organ function. Differential adhesion and paracrine signaling between neighboring tissues often influence the specific routes traveled by precursor cells during morphogenesis ([@bib61]). However, the molecular mechanisms through which tissue interactions guide organ assembly remain poorly understood.

Heart formation requires the coordinated movement of myocardial precursor cells from their bilateral origins toward the embryonic midline, where they meet and merge through a process called cardiac fusion ([@bib20]). Cardiac fusion is essential for the construction of the heart tube, which provides a fundamental foundation for subsequent steps in cardiac morphogenesis. During cardiac fusion, the medial movement of the myocardium is considered to be a collective cell behavior: the cardiomyocytes travel along relatively parallel paths with very little neighbor exchange ([@bib31]) and simultaneously form intercellular junctions and create a primitive epithelial sheet ([@bib40]; [@bib43]; [@bib67]; [@bib69]; [@bib77]). Whether these coherent patterns of myocardial movement reflect active migration or passive morphogenesis is not yet resolved ([@bib1]; [@bib16]; [@bib70]; [@bib73]; [@bib77]). In either case, it is important to elucidate the specific signals that dictate the medial direction of myocardial trajectories during cardiac fusion.

Several lines of evidence indicate that cardiac fusion is mediated by interactions between the myocardium and the adjacent anterior endoderm. In both mouse and zebrafish, mutations that block endoderm formation or disrupt endoderm integrity also inhibit cardiac fusion ([@bib2]; [@bib31]; [@bib33]; [@bib34]; [@bib37]; [@bib39]; [@bib44]; [@bib47]; [@bib53]; [@bib56]; [@bib58]; [@bib76]; [@bib78]). Studies tracking both endodermal and myocardial movement in chick have suggested that endodermal contraction provides a physical force that pulls the myocardium toward the midline ([@bib1]; [@bib14]; [@bib70]). However, while endodermal forces may influence initial phases of cardiac fusion, the observed patterns of endoderm behavior seem insufficient to account for the entire path traversed by the moving cardiomyocytes ([@bib1]; [@bib14]; [@bib70]; [@bib73]; [@bib77]). Moreover, observations of myocardial cell protrusions have suggested that these cells may actively migrate in response to endodermal cues ([@bib16]; [@bib27]; [@bib77]). While it is clear that the endoderm plays an important role in facilitating cardiac fusion, the molecular underpinnings of the endodermal-myocardial relationship are still unknown.

Here, we reveal a novel connection between the endoderm and myocardium by discovering a new role for platelet-derived growth factor (PDGF) signaling. PDGFs signal through receptor tyrosine kinases and are well known for their mitogenic activity ([@bib4]), as well as for their role in guiding the migration of mesenchymal cells ([@bib6]; [@bib75]). However, PDGF signaling has not been previously implicated in heart tube assembly, even though it is known to be important for later aspects of heart development, such as the contribution of cardiac neural crest cells to the outflow tract ([@bib48]; [@bib63]; [@bib68]), the formation of the inflow tract ([@bib9]), and the formation of epicardial derivatives ([@bib65]).

Our analysis of early morphogenetic defects caused by mutation of the gene encoding PDGF receptor alpha (Pdgfra) uncovers an essential function for Pdgfra during cardiac fusion in both zebrafish and mouse. Notably, through live imaging of individual cell movements in zebrafish mutants, we find that *pdgfra* is crucial for guiding cardiomyocyte movement toward the midline. Furthermore, our studies suggest that expression of PDGF ligands by the anterior endoderm could facilitate interaction of this tissue with the *pdgfra*-expressing myocardial precursors. Thus, our work supports a model in which PDGF signaling underlies communication between the endoderm and myocardium and thereby directs the cell movements that initiate heart tube assembly. These insights into the regulation of cardiomyocyte behavior provide new ideas regarding the etiology of diseases associated with aberrant cell movement ([@bib23]), including congenital heart diseases (CHDs) caused by defective myocardial morphogenesis ([@bib9]; [@bib11]; [@bib50]; [@bib60]).

Results {#s2}
=======

*refuse-to-fuse (ref)* mutants display cardiac fusion defects {#s2-1}
-------------------------------------------------------------

In a screen for ethylnitrosourea-induced mutations that disrupt cardiac morphogenesis in zebrafish ([@bib7]), we identified a recessive lethal mutation, *refuse-to-fuse* (*ref*), that causes abnormal cardiac chamber morphology. Instead of the normal curvatures of the wild-type ventricle ([Figure 1A](#fig1){ref-type="fig"}), *ref* mutants often displayed a bifurcated ventricle at 48 hours post-fertilization (hpf) ([Figure 1B](#fig1){ref-type="fig"}). This phenotype was the most common among a range of cardiac defects in *ref* mutants ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). On rare occasions, we found *ref* mutants with cardia bifida, a condition in which two separate hearts form in lateral positions ([Table 1](#tbl1){ref-type="table"}). The observed bifurcated ventricle and cardia bifida phenotypes led us to hypothesize that the *ref* mutation might interfere with cardiac fusion. In wild-type embryos, cardiac fusion results in the formation of a ring of cardiomyocytes at the midline by the 22 somite stage ([Figure 1C](#fig1){ref-type="fig"}). In contrast, *ref* mutant cardiomyocytes failed to fuse into a ring and instead remained in separate bilateral domains ([Figure 1D](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}) or fused only in posterior positions, creating a horseshoe shape ([Figure 1E](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Similar fusion defects were also observed when examining a broader portion of the anterior lateral plate mesoderm (ALPM) encompassing the heart fields ([Figure 1F,G](#fig1){ref-type="fig"} and Figure 5A--F).10.7554/eLife.21172.003Figure 1.Cardiac fusion defects in *refuse-to-fuse* (*ref*) mutants.(**A**,**B**) Three-dimensional reconstructions depict wild-type (wt) and *ref* mutant hearts expressing the myocardial reporter transgene *Tg(myl7:egfp)* at 48 hpf. In contrast to the normal contours of the wt heart (**A**), the *ref* mutant heart (**B**) often displays a bifurcated, two-lobed ventricle and a misshapen atrium. See [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"} for more information on the range of cardiac phenotypes observed in *ref* mutants at 48 hpf. A: atrium; V: ventricle. (**C**--**G**) Dorsal (**C**--**E**) and ventral (**F,G**) views, anterior to the top, of wt (**C,F**) and *ref* (**D,E,G**) mutant embryos displaying the expression of *myl7* at the 22 somite stage (22 s; **C**--**E**) and the localization of ZO-1 at the 18 somite stage (18 s; **F,G**). (**C**--**E**) In *ref* mutants at this stage, cardiomyocytes typically fail to fuse at the midline (**D**) or only fuse posteriorly (**E**). Note that the *ref* mutation is incompletely penetrant, although its penetrance is more evident at 20 s than at 48 hpf ([Table 2](#tbl2){ref-type="table"}), suggesting that some *ref* mutants recover as development proceeds. (**F,G**) ZO-1 localization highlights junctions forming within the maturing epithelium of the ALPM in both wt and *ref* mutant embryos. The ventral portion of the neural tube located at the midline is also visible. By 18 s, the wt ALPM (**F**) has initiated fusion at the midline, whereas the two sides of the *ref* mutant ALPM are still separate (**G**). Scale bars: 60 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.003](10.7554/eLife.21172.003)10.7554/eLife.21172.004Figure 1---figure supplement 1.*ref* mutant embryos display a range of cardiac defects.(**A,B**) Lateral views of live wild-type (wt, **A**) and *ref* mutant (**B**) embryos at 48 hpf. *ref* mutants exhibit a mild pericardial edema. (**C**--**F**) Lateral views from the right side of wt (**C**) and *ref* mutant (**D**--**F**) hearts reveal a variety of abnormal cardiac morphologies in *ref* mutants. The most commonly observed phenotype was a bifurcated ventricle (**D**), some other embryos exhibited abnormal looping (**E**) or a severely shrunken heart (**F**), and a few embryos had cardia bifida (not shown). See [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} for more information regarding the incomplete penetrance and variable expressivity of the *ref* mutant phenotype. (**C\'**--**F\'**) Cartoons outline the cardiac morphologies shown in **C**--**F**, with the ventricle in magenta and the atrium in green.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.004](10.7554/eLife.21172.004)10.7554/eLife.21172.005Figure 1---figure supplement 2.The anterior endoderm forms normally in *ref* mutant embryos.(**A**--**D**) Lateral views, dorsal to the right, depict the expression of *axial* at 8.5 hpf (**A,B**) or *sox17* at 8 hpf (**C,D**). The number and distribution of endoderm precursor cells is similar in wt (**A,C**) and *ref* mutant (**B**, n = 8/8; **D**, n = 14/14) embryos during gastrulation stages. (**E**--**H**) Dorsal views, anterior to the top, depict the anterior endoderm, visualized with the expression of *axial* at 24 hpf (**E,F**) or the endodermal reporter transgene *Tg(sox17:egfp)* at 18 s (**G,H**). The width and morphology of the anterior endoderm is similar in wt (**E,G**) and *ref* mutant (**F**, n = 13/13; **H**, n = 7/7) embryos during the stages when cardiac fusion takes place. Scale bars: 60 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.005](10.7554/eLife.21172.005)10.7554/eLife.21172.006Figure 1---figure supplement 3.Endocardial cells move to the midline in *ref* mutant embryos.(**A,B**) Dorsal views, anterior to the top, depict the expression of the endothelial reporter transgene *Tg(fli1a:negfp)* in the endocardial precursor population at 18 s (n = 8). In both wt (**A**) and *ref* mutant (**B**) embryos, the endocardial precursors move to the midline during the process of cardiac fusion. Scale bar: 60 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.006](10.7554/eLife.21172.006)10.7554/eLife.21172.007Table 1.Variable expressivity of cardiac phenotype in *ref* mutant embryos.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.007](10.7554/eLife.21172.007)StagePhenotypeNumber of embryos22 s^∗^No fusion8Only posterior fusion748 hpf^†^Bifurcated ventricle229Shrunken heart147Abnormal looping74Cardia bifida4[^1][^2]10.7554/eLife.21172.008Table 2.Penetrance of cardiac phenotype in *ref* mutant embryos.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.008](10.7554/eLife.21172.008)StageTotal \# embryos\# +/+ embryos\# +/− embryos\# −/− embryos\# with evident cardiac defectsApproximate penetrance22 s611427201575%48 hpf522NG^∗^NG^∗^NG^∗^5844%^†^[^3][^4]

Since prior studies in zebrafish have shown that defects in endoderm specification or morphogenesis can inhibit cardiac fusion ([@bib2]; [@bib31]; [@bib33]; [@bib34]; [@bib37]; [@bib44]; [@bib53]; [@bib76]; [@bib78]), we examined the status of the endoderm in *ref* mutants. During gastrulation stages, the specification and movement of endodermal cells appeared normal in *ref* mutants ([Figure 1---figure supplement 2A--D](#fig1s2){ref-type="fig"}). In addition, the differentiation and morphology of the anterior endoderm in *ref* mutants appeared intact during the stages when cardiac fusion takes place ([Figure 1---figure supplement 2E--H](#fig1s2){ref-type="fig"}). The normal appearance of the *ref* mutant endoderm was consistent with the unaltered progress of the endocardial precursor cells in *ref* mutants: endocardial cells require interactions with the anterior endoderm for their medial movement during cardiac fusion ([@bib31]; [@bib72]; [@bib73]), and the *ref* mutant endocardium seemed to reach the midline normally ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Taken together, our data suggest that defects in myocardial movement, as opposed to defects in the endoderm, cause the bifurcated cardiac morphology in *ref* mutants.

*ref* is a loss-of-function mutation in *pdgfra* {#s2-2}
------------------------------------------------

In order to identify the genomic lesion responsible for the *ref* mutant phenotype, we mapped the *ref* locus to a \<0.1 cM region on linkage group 20 containing six annotated genes ([Figure 2A](#fig2){ref-type="fig"}). Our examination of *ref* mutant cDNA revealed missplicing in one of these genes, *platelet-derived growth factor receptor alpha* (*pdgfra)* ([Figure 2B](#fig2){ref-type="fig"}). Specifically, we noted that exon 14 was omitted or truncated in the *pdgfra* messages detected in *ref* mutant cDNA. Furthermore, *ref* mutant genomic DNA contained a G-to-A mutation in the first nucleotide of intron 15 of *pdgfra* ([Figure 2C,D](#fig2){ref-type="fig"}). Since a G at the exon/intron boundary is an essential conserved feature of splice sites, we infer that this mutation would disrupt *pdgfra* splicing. The misspliced *pdgfra* messages found in *ref* mutants cause a frameshift in the coding sequence, resulting in a premature truncation prior to the transmembrane domain of Pdgfra ([Figure 2D](#fig2){ref-type="fig"}). In concordance with the concept that premature stop codons often lead to nonsense-mediated decay, we detected a global reduction of *pdgfra* mRNA in *ref* mutants ([Figure 2E,F](#fig2){ref-type="fig"}).10.7554/eLife.21172.009Figure 2.*ref* is a loss-of-function mutation in *pdgfra*.(**A**) Polymorphic markers (z21170, kdr_e28, 5'scfd2, z14614) were used to map meiotic recombination events, narrowing the region containing the *ref* mutation to \<0.1 cM on linkage group (LG) 20. (See also [Table 3](#tbl3){ref-type="table"}). Fractions indicate frequencies of proximal (magenta) and distal (green) recombination between markers and *ref*. Six annotated genes are present in this region (GRCv10); sequence analysis of *kdr*, *kita*, *gsx2*, *lnx1*, and *fip1l1a* in *ref* mutants revealed only missense mutations that led to conserved amino acid changes. (**B**) RT-PCR spanning exons 13--19 of *pdgfra* generates a single, properly spliced product from homozygous wt embryos and multiple, smaller products from *ref* mutant embryos. Sequencing revealed that exon 14 was either omitted or truncated in these smaller products; in all cases, the observed missplicing would result in a frameshift followed by a premature stop codon. Although we did not detect any normally spliced *pdgfra* products in *ref* mutants, we cannot rule out the presence of low levels of wild-type mRNA. RT-PCR of *gapdh* demonstrates use of comparable amounts of template. (**C,D**) Sequencing the e14i15 exon-intron boundary of *pdgfra* revealed that *ref* mutant genomic DNA contains a G-to-A mutation in a conserved intronic nucleotide required for proper splicing. Chromatograms (**C**) and sequence alignment (**D**) show position of the mutation relative to reference sequences. Schematics (**D**) depict the proteins predicted to result from the wt, *ref,* and *b1059* alleles of *pdgfra*; immunoglobulin (magenta), transmembrane (green), and tyrosine kinase (blue) domains are shown. (**E,F**) Lateral views depict expression of *pdgfra* at 11 s. Expression levels are lower in *ref* mutants (**F**; n = 5/5) than in wt (**E**). (**G**--**J**) Dorsal views, anterior to the top, of *myl7* expression at 22 s. In contrast to wt (**G**), cardiac fusion defects are evident in embryos injected with a *pdgfra* morpholino (MO) (**H**), *b1059* homozygous mutant embryos (**I**), and *ref/b1059* transheterozygous mutant embryos (**J**). See [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} for additional information on the prevalence of each of these phenotypes. Scale bars: 60 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.009](10.7554/eLife.21172.009)10.7554/eLife.21172.010Figure 2---figure supplement 1.*ref* mutants display craniofacial defects.(**A**--**F**) Lateral (**A**--**C**) and ventral (**D**--**F**) views of embryos at 6 days post-fertilization (dpf), stained with Alcian blue to show the dorsal and ventral cartilage in the head. Embryos homozygous for *ref* (**B**,**E**; n = 9/9) or transheterozgous for *ref* and *b1059* (**C**,**F**; n = 5/6) display similar dorsal cartilage formation defects. Specifically, the dorsal ethmoid plate is diminished or absent in these mutants. Scale bars: 60 μm. (**D\'**--**F\'**) Cartoons illustrate the dorsal cartilage structures shown in **D**--**F**.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.010](10.7554/eLife.21172.010)10.7554/eLife.21172.011Figure 2---figure supplement 2.Comparison of cardiac fusion phenotypes resulting from alteration of PDGF signaling.Bar graph compares severity of cardiac fusion phenotypes observed at 22 s in three sets of experiments: one set of experiments comparing *ref* homozygous mutant embryos, *b1059* homozygous mutant embryos, *ref/b1059* transheterozygous mutant embryos, *pdgfra* MO-injected embryos, and wt sibling embryos (as in [Figure 2G--J](#fig2){ref-type="fig"}); one set of experiments comparing embryos treated with DMSO and embryos treated with Pdgfr inhibitor V (as in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}); and one set of experiments comparing wt embryos and *Tg(hsp70l:pdgfaa-2A-mCherry)* embryos, following heat shock at the tailbud stage (as in [Figure 7Q--S](#fig7){ref-type="fig"}). Phenotypes were classified as fused (blue; as in [Figure 2G](#fig2){ref-type="fig"}), almost fused (light blue; no representative image shown), only posterior fusion (yellow; as in [Figure 2H](#fig2){ref-type="fig"}), or no fusion (red; as in [Figure 2J](#fig2){ref-type="fig"}). The n for each data set is presented under its corresponding bar. The severity of the cardiac fusion defects appears similar in *ref* homozygous mutant embryos, *b1059* homozygous mutant embryos, *ref/b1059* transheterozygous mutant embryos, and embryos treated with Pdgfr inhibitor V. In contrast, the phenotypes observed in *pdgfra* MO-injected embryos are less severe, possibly reflecting the efficacy of this MO. In addition, we note that the effects caused by mutation of *pdgfra* and overexpression of *pdgfaa* are relatively similar. The similarity in phenotypes caused by loss and gain of PDGF signaling is reminiscent of results obtained in studies of the role of PDGF signaling during *Xenopus* gastrulation ([@bib15]; [@bib49]).**DOI:** [http://dx.doi.org/10.7554/eLife.21172.011](10.7554/eLife.21172.011)

We next compared the *ref* mutant phenotype to the effects of another mutation in *pdgfra, b1059*. The *b1059* allele is a missense mutation that disrupts a conserved residue within the tyrosine kinase domain of Pdgfra ([@bib19]) ([Figure 2D](#fig2){ref-type="fig"}). Previous studies of *b1059* mutant embryos focused on their dorsal jaw defects ([@bib19]); our analysis also uncovered dorsal jaw defects in *ref* mutants ([Figure 2---figure supplement 1B,E](#fig2s1){ref-type="fig"}), as well as cardiac fusion defects in *b1059* mutants ([Figure 2G,I](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Through complementation testing, we found that *ref* and *b1059* fail to complement each other; transheterozygotes displayed defects in both cardiac fusion ([Figure 2J](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) and dorsal jaw formation ([Figure 2---figure supplement 1C,F](#fig2s1){ref-type="fig"}). Finally, we found that injection of a morpholino targeting *pdgfra* also interfered with cardiac fusion ([Figure 2H](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Together, our mapping, sequencing, complementation testing, and morpholino data support the conclusion that the *ref* mutation causes inappropriate splicing of *pdgfra*, resulting in diminished *pdgfra* function and cardiac fusion defects.

Mutation of *Pdgfra* disrupts heart tube assembly in mice {#s2-3}
---------------------------------------------------------

Although prior work in mouse has revealed functions for PDGF signaling during later stages of heart development ([@bib26]; [@bib57]; [@bib63]), these studies did not report an earlier role for PDGFRα during cardiac fusion or heart tube assembly. In contrast, analysis of the *Patch* (*Ph*) mutant, carrying a chromosome deletion including *Pdgfra*, did reveal early cardiac phenotypes, as well as yolk sac defects ([@bib51]). Exploration of the early functions of PDGFRα has been complicated by the variability of *Pdgfra* mutant phenotypes, due in part to genetic background ([@bib26]; [@bib52]; [@bib63]; [@bib66]; [@bib68]). Since the C57BL/6 background was reported to generate more severe phenotypes in the *Ph* mutant ([@bib51]), we chose to analyze mouse embryos carrying *Pdgfra* null alleles on a C57BL/6J background at E9.5, using expression of *Nkx2-5* to highlight heart morphology ([Figure 3A--E\'](#fig3){ref-type="fig"}). We note that we encountered *Pdgfra* null mutants on this background at E9.5 less often than predicted ([Table 4](#tbl4){ref-type="table"}), potentially because they fail to survive until this stage. Although the cause of this loss remains to be identified, it is consistent with the expression of *Pdgfra* during early embryogenesis (e.g. [@bib5]; [@bib54]; [@bib62]), and with studies in other vertebrates revealing a role for *Pdgfra* during gastrulation ([@bib49]; [@bib75]).10.7554/eLife.21172.012Figure 3.*Pdgfra* mouse mutants display defects in heart tube assembly.(**A**--**E\'**) Ventral views (**A,B,D,E**), lateral views (**A\',B\',C**), and transverse sections (**A\'\',E\'**) depict *Nkx2-5* expression in wt (**A**--**A\'\'**) and *Pdgfra* homozygous mutant (**B**--**E\'**) mice on a C57BL/6J background at E9.5. Some *Pdgfra* mutants display relatively mild cardiac defects (**B,B\'**), including defects in heart tube rotation. Other *Pdgfra* mutants display severe cardiac defects that could result from hindered cardiac fusion (**C**--**E\'**). These defects include incomplete heart tube assembly (**C,D**) with two inflow/common atrial regions (red arrows) and a single ventricle (black arrowhead) or with cardia bifida (**E**,**E\'**; arrows indicate unfused ventricles and atria). See [Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"} for additional information on the prevalence of mutant phenotypes. A: atrium; AVC: atrioventricular canal; LA: left atrium; LV: left ventricle; OFT: outflow tract; RA: right atrium; RV: right ventricle; V: ventricle. Scale bars: 100 μm. (**F**--**I**) Ventral views depict localization of *Pdgfra* mRNA (**F**--**H**) and PDGFRα protein (**I**) in wt embryos from E7.5 to E8.5. *Pdgfra* expression is seen in anterior lateral plate mesoderm (ALPM) at E7.5 (**F**) and persists in the caudal region of the forming heart at E8.0 (**G**; arrows) and in the inflow tract at E8.5 (**H**; arrows). *Pdgfra* is also expressed in somites (S) and caudal lateral plate mesoderm (LPM) at E8.0-E8.5. Although mRNA levels are diminished, PDGFRα protein localization is maintained throughout the forming heart at E8.0 (**I**). FH: forming heart; H: heart. (**J,J\'**) Ventral view (**J**) and transverse section (**J\'**) depict the localization of *Pdgfa* mRNA at E8.0. Black line in **J** indicates plane of transverse section shown in **J'**. At this stage, *Pdgfa* expression is seen in the foregut endoderm (Fg) and lateral ectoderm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.012](10.7554/eLife.21172.012)10.7554/eLife.21172.013Table 3.Primers used to map recombinants.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.013](10.7554/eLife.21172.013)MarkerForward primerReverse primer5'SCFD2CGCGTTACCAGAGAGACACATTCTCGGCAGGATAAATTGGZ14614AAACACATGCACAATGGTAGAAACAGCAAGTTCAGCCAAAACAZ21170AAACATTGCTTTTGGCCACTCTCACTCCCCCACACTGTTTkdr_e28TATGATAACGCTCCGCCTCTCAGGGGAATGTCCACAAAAC10.7554/eLife.21172.014Table 4.Genotypes encountered in progeny from intercrosses of *Pdgfra* heterozygotes at E9.5.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.014](10.7554/eLife.21172.014) TotalWild-typeHeterozygous mutantHomozygous mutantNumber of embryos10830^∗^64^∗^14^†^Observed ratio0.92.00.4^‡^Expected ratio1.02.01.0[^5][^6][^7]

Our analysis revealed a range of early defects in cardiac morphogenesis in homozygous *Pdgfra* mutants at E9.5 ([Figure 3A--E\'](#fig3){ref-type="fig"}; [Table 5](#tbl5){ref-type="table"}). Wild-type hearts had undergone looping and exhibited distinct left and right atrial and ventricular chambers ([Figure 3A--A\'\'](#fig3){ref-type="fig"}). Some *Pdgfra* homozygous mutant hearts displayed relatively mild defects in heart looping as well as in the size and shape of the cardiac chambers and their inflow and outflow tracts ([Figure 3B,B\'](#fig3){ref-type="fig"}). Other *Pdgfra* mutant hearts displayed more severe disruptions that could be the consequence of abnormal cardiac fusion ([Figure 3C--E\'](#fig3){ref-type="fig"}): the most prominent were embryos with a split inflow/common atrial region connected to a single ventricle ([Figure 3C,D](#fig3){ref-type="fig"}), and we also observed a single embryo with near total cardia bifida ([Figure 3E,E\'](#fig3){ref-type="fig"}). *Pdgfra* mutants were often smaller than wild-type littermates, consistent with previous observations ([@bib51]); however, the observed severe cardiac defects (C-E\') are not likely a result of general developmental delay, as these mutant phenotypes do not resemble wild-type cardiac morphology at younger stages. Severely affected embryos had not turned, as previously observed ([@bib66]). We did not observe omphalocele as reported ([@bib66]), although these previous observations were made at later time points than examined here. The majority of *Pdgfra* mutants died by E10.5, slightly earlier than reported for the majority of *Ph* mutants ([@bib51]). Altogether, our data uncover a previously unappreciated influence of *Pdgfra* on the early stages of cardiac morphogenesis in mice. In combination with the phenotype of *ref* mutants, these studies suggest that Pdgfra plays a conserved role in regulating heart tube assembly.10.7554/eLife.21172.015Table 5.Cardiac phenotypes observed in *Pdgfra* mutants at E9.5.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.015](10.7554/eLife.21172.015)Number of embryosTotal14Normal phenotype2Abnormal looping5Split inflow/common atrial region6Cardia bifida1

*pdgfra* is expressed within the ALPM while cardiac fusion is underway {#s2-4}
----------------------------------------------------------------------

To further elucidate how Pdgfra influences heart tube assembly, we next examined the expression pattern of *pdgfra* during cardiac fusion in zebrafish. We found robust expression of *pdgfra* within the ALPM and in migrating neural crest cells ([Figure 4A--D](#fig4){ref-type="fig"}). The domains of *pdgfra* expression in the ALPM matched those of *hand2* ([Figure 4E--J](#fig4){ref-type="fig"}), which is expressed in the territories that contain myocardial precursor cells and is excluded from the territories containing endocardial precursors ([@bib64]). As cardiac fusion proceeds, *hand2* continues to be expressed in the cardiomyocytes that reach the midline ([Figure 5A--C](#fig5){ref-type="fig"}), while *pdgfra* expression appears to be absent from these cells ([Figure 4D](#fig4){ref-type="fig"}).10.7554/eLife.21172.016Figure 4.*pdgfra* is expressed within the ALPM while cardiac fusion is underway.(**A**--**D**) Dorsal views, anterior to the top, depict *pdgfra* expression in wt embryos at 10 s (**A**), 12 s (**B**), 14 s (**C**), and 18 s (**D**). Arrows (**A**) indicate *pdgfra* expression in the ALPM and the neural crest (NC). Asterisk (**D**) denotes position of the myocardium by 18 s; although *pdgfra* is expressed in the myocardial precursors within the ALPM at earlier stages, its expression in these cells appears to be gone by this time point. (**E**--**J**) Comparison of *hand2* (green) and *pdgfra* (red) expression patterns demonstrates their overlap in the wt ALPM at 10 s. (**E**--**G**) Three-dimensional confocal reconstructions of dorsal views, anterior to the top, focused on the left side of the ALPM (area outlined by a dashed box in (**A**). Arrows (**E**) indicate *pdgfra* expression in the ALPM and the NC. ([**H**]{.smallcaps}--**J**) Single transverse (XZ) sections from (**E**--**G**), respectively. Yellow arrow (**H**) indicates overlap of *hand2* and *pdgfra* expression in the ALPM. (**K**--**P**) Comparison of *axial* (green) and *pdgfra* (red) expression patterns demonstrates lack of *pdgfra* expression in the *axial*-expressing anterior endoderm in wt embryos at 12 s. (**K**--**M**) Three-dimensional confocal reconstructions of dorsal views, anterior to the top; arrows (**K**) indicate *pdgfra* expression in the ALPM and the neural crest. (**N**--**P**) Single transverse (XZ) sections from (**K**--**M**), respectively. Arrowheads (**N**) indicate *axial* expression in the anterior endoderm, adjacent to, but not overlapping with, *pdgfra* expression in the ALPM. Scale bars: 60 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.016](10.7554/eLife.21172.016)

Similarly, we found that mouse *Pdgfra* is expressed in the ALPM at E7.5 ([Figure 3F](#fig3){ref-type="fig"}) and later becomes confined to the caudal aspect of the forming heart tube by E8.0 ([Figure 3G](#fig3){ref-type="fig"}) and to the inflow tract of the looping heart ([Figure 3H](#fig3){ref-type="fig"}) as well as the dorsal mesocardium ([@bib55]) by E8.5. In more mature hearts, *Pdgfra* is expressed in the atrioventricular valves and epicardium ([@bib13]; [@bib51]). Even though *Pdgfra* mRNA levels had declined in the anterior cardiac mesoderm by the beginning of heart tube formation ([Figure 3G](#fig3){ref-type="fig"}), we found persistent PDGFRα protein expression in the forming heart at this stage ([Figure 3I](#fig3){ref-type="fig"}). PDGFRα was also found in the more caudal domains defined by *Pdgfra* mRNA expression, including the caudal aspect of the forming heart corresponding to its future inflow tract and coelomic mesothelium ([Figure 3I](#fig3){ref-type="fig"}) ([@bib8]).

We did not observe *pdgfra* expression within the anterior endoderm during cardiac fusion in either zebrafish or mouse ([Figures 3G](#fig3){ref-type="fig"} and [4K--P](#fig4){ref-type="fig"}; \[[@bib55]\]). In zebrafish, comparison of *axial* and *pdgfra* expression demonstrated mutually exclusive expression domains ([Figure 4K--P](#fig4){ref-type="fig"}). Lack of *pdgfra* expression in the anterior endoderm is also consistent with previous expression analysis in mouse ([@bib52]), as well as with the lack of anterior endoderm defects in *ref* mutant embryos ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Altogether, the *pdgfra* expression patterns in both zebrafish and mouse indicate that *pdgfra* could act within the ALPM to regulate the progression of cardiac fusion.

*pdgfra* controls the medial direction of cardiomyocyte movement during cardiac fusion {#s2-5}
--------------------------------------------------------------------------------------

Although our analysis pointed toward a role for *pdgfra* within the ALPM during cardiac fusion, we also considered the possibility that *pdgfra* expression in the early embryo ([@bib6]; [@bib42]; [@bib45]; [@bib75]) could indirectly affect cardiac fusion by influencing processes such as mesoderm involution during gastrulation ([@bib75]). However, we did not observe any defects in the size, shape, or bilateral spacing of the ALPM in *ref* mutants at the 8--12 somite stages ([Figure 5A,D,G](#fig5){ref-type="fig"}), indicating that early ALPM morphogenesis is intact in these embryos. Moreover, we found that pharmacological inhibition of Pdgfr activity at the tailbud stage can disrupt cardiac fusion ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), further supporting the conclusion that *pdgfra* activity influences cardiac fusion after gastrulation is complete.10.7554/eLife.21172.017Figure 5.*pdgfra* influences the movement of the ALPM after the 15 somite stage.(**A**--**F**) Dorsal views, anterior to the top, depict expression of *hand2* in the wt (**A**--**C**) and *ref* mutant (**D**--**F**) ALPM from 12 to 20 s. The morphology and position of the ALPM are indistinguishable in wt (**A**) and *ref* mutant (**D**) embryos at 12 s. After 15 s (**B,C,E,F**), disrupted movement of the ALPM is evident in *ref* mutants. Scale bar: 60 μm. (**G**) Graph illustrates the average distance between the two sides of the ALPM in wt and *ref* mutant embryos from 8 to 20 s. In each embryo, the distance between the sides of the ALPM was calculated by measuring the distance between the medial edges of the *hand2*-expressing domains at three equidistant points (200 μm apart) along the anterior-posterior axis. The largest of those three measurements was selected as representative of the maximum distance between the bilateral ALPM domains for that embryo. Dots represent the selected measurements from individual embryos. The distance between the bilateral sheets in *ref* mutant embryos begins to diverge significantly from wt after 15 s. Error bars represent the standard error. Asterisks indicate p\<0.05 (Student's t-test): p=0.99 at 8 s; p=0.58 at 12 s; p=0.30 at 14 s; p=0.053 at 15 s; p=0.012 at 16 s; and p=0.00012 at 20 s.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.017](10.7554/eLife.21172.017)10.7554/eLife.21172.018Figure 5---figure supplement 1.PDGF signaling is required after gastrulation for proper cardiac fusion.(**A,B**) Dorsal views, anterior to the top, display *myl7* expression at 22 s in representative embryos treated with DMSO (**A**) or Pdgfr inhibitor V (**B**) from the tailbud stage until 22 s. DMSO-treated control embryos exhibited normal cardiac fusion, whereas treatment with Pdgfr inhibitor V disrupted cardiac fusion. See [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} for additional information on the prevalence of these phenotypes. Scale bar: 60 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.018](10.7554/eLife.21172.018)10.7554/eLife.21172.019Figure 5---figure supplement 2.Overexpression of *pdgfaa* influences ALPM movement by the 15 somite stage.(**A**--**C**) Dorsal views, anterior to the top, depict expression of *hand2* in the ALPM of *Tg(hsp70l:pdgfaa-2A-mCherry)* embryos from 12 to 20 s, following heat shock at the tailbud stage. See [Figure 5A--C](#fig5){ref-type="fig"} for images of representative wt embryos at the same stages. Overexpression of *pdgfaa* at the tailbud stage does not seem to affect the morphology and position of the ALPM at 12 s (**A**), but it does disrupt ALPM movement by 16 s (**B**) and 20 s (**C**). Scale bar: 60 μm. (**D**) Graph illustrates the average distance between the two sides of the ALPM from 12 to 20 s in *Tg(hsp70l:pdgfaa-2A-mCherry)* embryos, following heat shock at the tailbud stage, shown together with the data presented in [Figure 5G](#fig5){ref-type="fig"}. The distance between the sides of the ALPM domains in transgenic embryos was measured as described for [Figure 5G](#fig5){ref-type="fig"}. Dots represent measurements from individual embryos. The distance between the bilateral sheets of ALPM in *Tg(hsp70l:pdgfaa-2A-mCherry)* embryos begins to diverge significantly from wt by 15 s. Error bars represent the standard error. Asterisks indicate p\<0.05 in comparison to wt embryos (Student's T-test): p=0.47 at 12 s; p=0.12 at 14 s; p=0.024 at 15 s; p=0.090 at 16 s; and p=0.000027 at 20 s.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.019](10.7554/eLife.21172.019)

To determine when cardiac fusion first goes awry in *ref* mutants, we began by comparing the distance between the left and right sides of the ALPM in wild-type and *ref* mutant embryos. Until the 15 somite stage, the spacing between the bilateral domains of the ALPM was normal in *ref* mutants ([Figure 5G](#fig5){ref-type="fig"}). After the 15 somite stage, the *ref* mutants began to display an evident phenotype: whereas the two sides of the wild-type ALPM continued to move toward each other, the sides of the *ref* mutant ALPM stayed apart ([Figure 5B,C,E,F,G](#fig5){ref-type="fig"}). Thus, although the initial stages of ALPM convergence are unaffected in *ref* mutants, the *ref* mutant ALPM is unable to approach the midline normally during cardiac fusion.

We next sought to elucidate the cellular defects responsible for the inhibition of cardiac fusion in *ref* mutants. Do *ref* mutant cardiomyocytes move at a sluggish rate or are they misdirected? Previous studies have shown that VEGF signaling can regulate the speed of endocardial precursor movement during cardiac fusion ([@bib21]), suggesting the possibility that PDGF signaling might set the pace of myocardial precursor movement. Alternatively, PDGF signaling has been shown to control the direction of mesodermal movement during gastrulation ([@bib15]; [@bib49]), suggesting that it could also guide the route taken by myocardial cells during cardiac fusion. To test these hypotheses, we tracked individual cell movements over time, using the myocardial reporter transgene *Tg(myl7:egfp)* ([@bib31]; [@bib32]) to follow the patterns of cardiomyocyte behavior in live embryos ([Figure 6](#fig6){ref-type="fig"}).10.7554/eLife.21172.020Figure 6.*pdgfra* regulates the directionality of cardiomyocyte movement.(**A**--**F**) Representative timelapse experiments indicate patterns of cell movement in wt (**A,B**) and *ref* mutant (**C**--**F**) embryos carrying the *Tg(myl7:egfp)* transgene. (**A,C,E**) Three-dimensional confocal reconstructions of select timepoints within each timelapse depict the typical changes in myocardial morphology seen over time in wt (**A**), mildly affected *ref* mutant (**C**) and severely affected *ref* mutant (**E**) embryos. (**B,D,F**) Tracks show the movements of the innermost cardiomyocytes in these embryos over the course of a \~2 hr timelapse. Cell tracks are colored from blue to red, indicating the location of each cell from the beginning to the end of its trajectory. See also [Videos 1](#media1){ref-type="other"}--[3](#media3){ref-type="other"}. Scale bar: 60 μm. (**G**--**L**) Quantitative analysis of cardiomyocyte movements. 168 and 137 cells were analyzed from eight wt and six *ref* mutant embryos, respectively. Graphs depict the average speed of individual cells (**G**, distance/time), the average efficiency index of individual cells (**H**, displacement/distance), the average velocity (displacement/time) of individual cells along the anterior-posterior axis (**I**) and along the medial-lateral axis (**J**), the average medial-lateral velocity per embryo (**K**), and the direction of the overall trajectory of individual cells (**L**). Dots in (**J**) are colored to depict the embryo to which they belong, and the same color scheme is used in (**K**). In (**L**), individual cells are grouped into 10 bins based on their net direction of movement; length of each radial bar represents the number of cells in each bin. The velocity along the medial-lateral axis (**J,K**) and the direction of cell trajectories (**L**) were significantly altered in *ref* mutants, indicating the misdirection of *ref* mutant cardiomyocytes and implicating *pdgfra* in steering the medial direction of cardiomyocyte movement. Error bars represent the standard deviation; p values were determined using Student's T-test.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.020](10.7554/eLife.21172.020)

We initiated our timelapse analysis at the 16 somite stage, the earliest timepoint when we could robustly detect *Tg(myl7:egfp)* expression. Consistent with our analysis of ALPM position ([Figure 5](#fig5){ref-type="fig"}), the bilateral populations of cardiomyocytes in *ref* mutants were already slightly farther apart than their wild-type counterparts were at the 16 somite stage ([Figure 6A,C,E](#fig6){ref-type="fig"}). By following the movements of these cells during cardiac fusion, we found that wild-type cardiomyocytes display a coherent pattern of collective movement without significant neighbor exchange ([Figure 6A,B](#fig6){ref-type="fig"}), consistent with our prior work ([@bib31]). Cardiomyocytes in *ref* mutants exhibited similar patterns of coherent movement ([Figure 6C--F](#fig6){ref-type="fig"}). However, while wild-type cardiomyocytes moved progressively toward the midline ([Figure 6A,B](#fig6){ref-type="fig"}; [Video 1](#media1){ref-type="other"}), the medial movement of *ref* mutant cardiomyocytes seemed severely diminished, even though these cells still appeared to be in motion ([Figure 6C--F](#fig6){ref-type="fig"}; [Videos 2](#media2){ref-type="other"}--[3](#media3){ref-type="other"}). In *ref* mutants with a relatively mild phenotype, a posterior subset of cardiomyocytes still exhibited sufficient medial movement to fuse at the midline ([Figure 6C,D](#fig6){ref-type="fig"}; [Video 2](#media2){ref-type="other"}). In more severely affected *ref* mutants, medial movement appeared lost along the entire anterior-posterior extent of the myocardium ([Figure 6E,F](#fig6){ref-type="fig"}; [Video 3](#media3){ref-type="other"}).Video 1.Cardiomyocytes in a wild-type embryo undergo medially directed movement during cardiac fusion.(A,B) Representative timelapse movie (A) and associated tracks (B) of cardiomyocyte movement occurring during cardiac fusion in a wild-type embryo carrying the *Tg(myl7:egfp)* transgene. (A) Movie of drift-corrected three-dimensional reconstructions of 30 confocal slices taken at \~4 min intervals for \~2 hr, starting when eGFP could first be detected in the ALPM. (B) The movements of individual cardiomyocytes at the innermost region of the ALPM were tracked (dots, B) at each time point. Their positions over the previous 80 min are depicted as connected colored tracks (blue-to-red, beginning-to-end). Blank frames indicate brief pauses in acquisition for refocusing. Arrows indicate initial starting position of cardiomyocytes. Asterisks indicate GFP^+^ cells that are not cardiomyocytes. Scale bar: 40 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.021](10.7554/eLife.21172.021)10.7554/eLife.21172.021Video 2.Not all cardiomyocytes in a mildly affected *ref* mutant embryo undergo medially directed movement during cardiac fusion.(A,B) Representative timelapse movie (A) and associated tracks (B) of cardiomyocyte movement in a mildly affected *ref* mutant embryo carrying the *Tg(myl7:egfp)* transgene. Images were acquired as described for [Video 1](#media1){ref-type="other"}; however, drift correction was not applied to this movie and thus its tracks were not included in further quantitative analysis. In mildly affected *ref* mutant embryos, posterior cardiomyocytes display sufficient medial movement to fuse at the midline, while anterior cardiomyocytes do not. Arrows indicate initial starting position of cardiomyocytes. Asterisks indicate GFP^+^ cells that are not cardiomyocytes. Scale bar: 40 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.022](10.7554/eLife.21172.022)10.7554/eLife.21172.022Video 3.Cardiomyocytes in a severely affected *ref* mutant embryo fail to display medially directed movement during cardiac fusion.(A,B) Representative timelapse movie (A) and associated tracks (B) of cardiomyocyte movement in a severely affected *ref* mutant embryo carrying the *Tg(myl7:egfp)* transgene. Images were acquired as described for [Video 1](#media1){ref-type="other"}, with drift correction. In severely affected *ref* mutant embryos, none of the cardiomyocytes display measurable medial movement. Arrows indicate initial starting position of cardiomyocytes. Blank frames indicate brief pauses in acquisition for refocusing. Asterisks indicate GFP^+^ cells that are not cardiomyocytes. Scale bar: 40 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.023](10.7554/eLife.21172.023)10.7554/eLife.21172.023

Lack of medial movement could be the result of defects in several aspects of cell behavior including speed, efficiency, and directionality. To distinguish between these possibilities, we performed quantitative analysis of individual cardiomyocyte trajectories. Compared to wild-type cardiomyocytes, *ref* mutant cardiomyocytes moved at a slightly slower average speed (distance/time) ([Figure 6G](#fig6){ref-type="fig"}) and with a slightly reduced efficiency (displacement/distance) ([Figure 6H](#fig6){ref-type="fig"}). When examining velocity (displacement/time) along particular axes, we found no difference between the velocities of wild-type and *ref* mutant cardiomyocyte movement along the anterior-posterior axis ([Figure 6I](#fig6){ref-type="fig"}). However, there was a substantial difference between the velocities of wild-type and *ref* mutant cardiomyocyte movement along the medial-lateral axis: the average velocity along the medial-lateral axis was 0.19 micron/min for wild-type cardiomyocytes, but was only 0.016 micron/min for *ref* mutant cardiomyocytes ([Figure 6J](#fig6){ref-type="fig"}). This difference in cell behavior becomes even more striking when considering the variability in the *ref* mutant phenotype. Two of the six *ref* mutant embryos examined had a relatively mild phenotype, and the cardiomyocytes in these embryos exhibited an average medial-lateral velocity similar to that seen in wild-type embryos ([Figure 6K](#fig6){ref-type="fig"}). In contrast, the other four *ref* mutant embryos displayed a more severe phenotype, and the cardiomyocytes in these embryos had an average medial-lateral velocity near or below zero ([Figure 6K](#fig6){ref-type="fig"}). Further examination of the vectors of cell movement revealed that these deficiencies in medial-lateral velocity reflect the misdirection of *ref* mutant cardiomyocytes. In our wild-type timelapse data, almost all cardiomyocytes move in the medial direction, whereas over half of the cardiomyocytes in our *ref* mutant timelapse data show no medial movement, with many of these cells moving away from the midline ([Figure 6L](#fig6){ref-type="fig"}). Together, these data reveal that *pdgfra* plays an important role in steering cardiomyocyte movement toward the midline during cardiac fusion.

The Pdgfra ligand *pdgfaa* is expressed in the anterior endoderm, adjacent to the ALPM {#s2-6}
--------------------------------------------------------------------------------------

We next evaluated whether the expression patterns of genes encoding Pdgfra ligands could provide insight into how PDGF signaling confers directionality to cardiomyocyte movement. Initial examination demonstrated that both *pdgfaa* and *pdgfab*, but not *pdgfc*, are expressed in bilateral medial stripes within the anterior portion of the embryo ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Deeper analysis of *pdgfaa* expression revealed that it is expressed in bilateral domains within the anterior endoderm between the 10 and 16 somite stages, positioned near the lateral edges of this tissue ([Figure 7A--J](#fig7){ref-type="fig"}). The expression of *pdgfaa* within the anterior endoderm in zebrafish is grossly consistent with prior studies demonstrating expression of *Pdgfa* in the mouse foregut ([@bib54]). We readdressed this issue in mouse and found *Pdgfa* expression in endoderm at the rim of the foregut pocket ([Figure 3J](#fig3){ref-type="fig"}) as well as in the pharyngeal floor and pharyngeal pouches ([Figure 3J\'](#fig3){ref-type="fig"}), regions closely associated with the forming heart tube at E8.0 and earlier stages. Moreover, the *pdgfaa* expression domains in zebrafish are medially adjacent to the positions of the myocardial precursors within the ALPM ([Figure 7K--P](#fig7){ref-type="fig"}), suggesting the possibility of a paracrine relationship between Pdgfa ligands in the endoderm and Pdgfra in the ALPM.10.7554/eLife.21172.024Figure 7.*pdgfaa* is expressed in the anterior endoderm, medially adjacent to the ALPM.(**A**--**G**) Fluorescent in situ hybridization and immunofluorescence compare the expression of *pdgfaa* (magenta) and *Tg(sox17:egfp)* (green) in wt embryos at 13 s. (**A**--**C**) Dorsal views, anterior to the top, of a three-dimensional reconstruction show that *pdgfaa* is expressed in bilateral domains of the anterior endoderm, near the lateral edges of the endodermal sheet. Expression of *pdgfaa* is also evident in cranial rhombomeres. (**D**--**F**) A coronal (XY) slice of the same embryo demonstrates the overlap between *pdgfaa* and *Tg(sox17:egfp)* expression. (**G**) A sagittal (ZY) slice of the same embryo provides a lateral view. (**H**--**J**) Transverse cryosections compare the expression of *pdgfaa* (blue) and the expression of *Tg(sox17:egfp)* (green) in wt embryos at 13 s, showing that *pdgfaa* is expressed in lateral domains of the endodermal sheet. (**K**--**P**) Comparison of *hand2* (green) and *pdgfaa* (red) expression patterns demonstrates that *pdgfaa* is expressed medially adjacent to the domains of *hand2* expression in the ALPM. (**K**--**M**) Three-dimensional confocal reconstructions of dorsal views, anterior to the top. (**N**--**P**) Single transverse (XZ) slices from (**K**--**M**), respectively. (**Q**--**S**) Dorsal views, anterior to the top, display the expression of *myl7* at 22 s in nontransgenic (**Q**) or *Tg(hsp70l:pdgfaa-2A-mCherry)* (**R,S**) embryos, following heat shock at the tailbud stage. Ectopic expression of *pdgfaa* causes cardiac fusion defects. See [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} for additional information regarding this phenotype. Scale bars: 60 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.024](10.7554/eLife.21172.024)10.7554/eLife.21172.025Figure 7---figure supplement 1.Expression of genes encoding Pdgfra ligands.(**A**--**C**) Dorsal views, anterior to the top, display expression of *pdgfaa* (**A**), *pdgfab* (**B**), and *pdgfc* (**C**) in wt embryos at 14 s. Since Pdgfa homodimers and Pdgfc homodimers have been shown to interact with Pdgfra ([@bib4]), we chose to examine the expression of the two zebrafish *Pdgfa* homologs, *pdgfaa* and *pdgfab*, as well as the expression of *pdgfc* ([@bib19]). Both *pdgfaa* (**A**) and *pdgfab* (**B**) are expressed in bilateral medial stripes (arrows, **A**), consistent with the location of the anterior endoderm. We detected *pdgfc* (**C**) expression in the otic vesicles and somites at 14 s, but we did not detect expression over background levels within the anterior endoderm. Scale bar: 60 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.025](10.7554/eLife.21172.025)

To investigate whether the spatially restricted expression of *pdgfa* genes is important for the regulation of cardiac fusion, we induced *pdgfaa* expression throughout the embryo using the heat-inducible transgene *Tg(hsp70l:pdgfaa-2A-mCherry).* Following heat shock at the tailbud stage, transgenic embryos displayed cardiac fusion defects similar to those observed in *ref* mutants ([Figure 7Q--S](#fig7){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). The ability of ectopic *pdgfaa* expression to disrupt cardiac fusion indicates that PDGF signaling has the potential to serve as an instructive influence in directing cardiomyocytes toward the midline.

Discussion {#s3}
==========

Taken together, our studies point to a model in which the PDGF signaling pathway facilitates communication between the endoderm and the myocardium and thereby directs cardiomyocytes toward the midline during cardiac fusion. We propose that Pdgfa ligands, produced by the anterior endoderm, signal through the Pdgfra receptor in the ALPM in order to control the directionality of cardiomyocyte behavior. This connection parallels other examples in which PDGF ligand-receptor pairs in adjacent tissues influence cell movements (e.g. in the kidney, neural crest, and gastrulating mesoderm \[[@bib19]; [@bib41]; [@bib75]\]), highlighting a paradigm for how tissue-tissue interactions establish the landscape of organogenesis ([@bib4]; [@bib30]; [@bib52]). Importantly, our demonstration of this new function for PDGF signaling represents the first insight into a pathway that guides the medial direction of cardiomyocyte movement. Moreover, our findings suggest a previously unappreciated molecular basis for the interactions between the endoderm and the myocardium that govern cardiac fusion. Further elucidation of the paracrine relationship between Pdgfa ligands in the endoderm and the Pdgfra receptor in the ALPM awaits the development of appropriate tools for the tissue-specific inactivation of these players.

How might PDGF signaling confer directionality on the collective behavior of the cardiomyocytes? In the absence of *pdgfra* function, myocardial movement is no longer directed toward the midline, implicating PDGF signaling in the arrangement of the forces that steer this epithelial tissue. One intriguing possibility is that PDGF signaling could direct medial movement via polarized Pdgfra activation that controls oriented formation of active protrusions, akin to the activity of the PDGF/VEGF receptor Pvr in *Drosophila*, which directs the collective movement of the epithelial border cells during oogenesis and the epidermal cells during dorsal closure ([@bib18]; [@bib25]). Alternatively, PDGF signaling could promote other types of epithelial reorganization that could facilitate directional movement, such as the rearrangement of adherens junctions or extracellular matrix at the medial edge of the myocardium, causing epithelial deformations that drive movement forward ([@bib74]; [@bib75]). Future examination of the relationship of PDGF signaling to the subcellular characteristics of the myocardium during cardiac fusion will help to elucidate the precise morphogenetic consequences of Pdgfra activity.

It is likely that the PDGF signaling pathway works in parallel with additional pathways to influence cardiac cell movement during cardiac fusion. Although *ref* mutants fail to undergo proper cardiac fusion, they do not fully phenocopy mutants with primary endoderm defects (e.g. *casanova* (*cas; sox32*) or *miles apart* (*mil; s1pr2*) \[[@bib2]; [@bib34]; [@bib37]; [@bib76]; [@bib78]\]). In *cas* and *mil* mutants, both the endocardial and myocardial precursors fail to move to the midline ([@bib31]; [@bib72]; [@bib73]); moreover, their myocardial movement defects can be detected prior to the eight somite stage ([@bib77]). In contrast, the endocardial precursors seem to reach the midline normally in *ref* mutants, and the *ref* myocardial movement defects emerge only after the 15 somite stage. Most likely, other factors, such as VEGF signaling to the endocardium ([@bib21]) or mechanical forces from the endoderm ([@bib1]; [@bib70]), collaborate with PDGF signaling to control distinct aspects of endocardial and myocardial cell behavior during earlier and later phases of cardiac fusion.

The cardiomyocyte movements that occur during cardiac fusion, guided by interactions with the endoderm, establish a foundation of proper tissue orientation and morphology upon which to assemble the initial heart tube. Our studies in zebrafish and mouse reveal a conserved influence of PDGF signaling on heart tube assembly. This influence is likely to be relevant to CHD in humans, since defects in cardiac morphology can originate in the cardiac precursor populations involved in cardiac fusion and heart tube assembly ([@bib55]; [@bib71]). More generally, the molecular mechanisms that control the direction of cardiomyocyte movement are likely to be relevant to the etiology of disorders that are caused by anomalous cell movement, potentially including ventricular septal defects, atrial septal defects, outflow tract defects, and trabeculation abnormalities ([@bib8]; [@bib12]; [@bib17]; [@bib50]; [@bib60]), as well as inflow tract defects known to be associated with mutations in *PDGFRA* ([@bib9]). *PDGFRA* is deleted in a number of human families showing total anomalous pulmonary venous return (TAPVR), in which the pulmonary arteries connect with the systemic venous system instead of the left atrium, a defect replicated in mouse and chick loss-of-function models ([@bib9]). TAPVR occurs in 1 in 15,000 live births and, while life-threatening, is at the mild end of the spectrum of morphogenetic defects that we have observed in *Pdgfra* knockout mice. Thus, our studies suggest the possibility of a broader involvement of *PDGFRA* mutations in CHD, specifically through their effects on heart tube assembly, and more globally as part of the spectrum of diseases associated with aberrant cardiac cell movements.

Materials and methods {#s4}
=====================

Zebrafish {#s4-1}
---------

We used the following transgenic and mutant strains of zebrafish: *Tg(myl7:egfp)^twu34^* ([@bib32]) (RRID:[ZFIN_ZDB-GENO-050809-10](https://scicrunch.org/resolver/ZFIN_ZDB-GENO-050809-10)), *Tg(fli1a:negfp)^y7^* ([@bib59]) (RRID:[ZFIN_ZDB-GENO-060821-2](https://scicrunch.org/resolver/ZFIN_ZDB-GENO-060821-2)), *Tg(sox17:egfp)^ha01^* ([@bib46]) (RRID:[ZFIN_ZDB-GENO-080714-2](https://scicrunch.org/resolver/ZFIN_ZDB-GENO-080714-2)), pdgfra^b1059^ ([@bib19]) (RRID:[ZFIN_ZDB-GENO-081008-1](https://scicrunch.org/resolver/ZFIN_ZDB-GENO-081008-1)), and *ref* (*pdgfra^sk16^*; this paper). The *Tg(hsp70l:pdgfaa-2A-mCherry)^sd44^* transgene was assembled using the D-Topo vector (Invitrogen, Carlsbad, CA) with a *pdgfaa* cDNA lacking the stop codon ([@bib19]), in combination with established Gateway cloning vectors ([@bib38]). The final destination vector was created by inserting a Cryaa:CFP cassette ([@bib29]) into the pDestTol2pA4 vector (gift from K. Kwan). Transgenic founders were established using standard techniques for Tol2-mediated transgenesis ([@bib22]). We analyzed F2 embryos from four separate transgenic lines to evaluate the effect of *pdgfaa* overexpression on cardiac fusion. Embryos were heat shocked at 38°C for 45 min beginning at the tailbud stage and were then returned to 28°C. Transgenic and nontransgenic sibling embryos were distinguished based on their expression of mCherry following heat shock. All zebrafish work followed protocols approved by the UCSD IACUC.

Mice {#s4-2}
----

*Pdgfra* null embryos were generated by intercrossing heterozygous *Pdgfra^tm11(EGFP)Sor ^*([@bib28]) (RRID:[MGI:5519063](https://scicrunch.org/resolver/MGI:5519063)) mutant mice on a co-isogenic C57BL/6J background. In situ hybridization and immunohistochemistry were performed using standard protocols ([@bib55]), and genotyping was performed as described for Jax stock \#007669 (<https://www.jax.org/strain/007669>). Images were captured using a Leica M125 microscope outfitted with a Leica DFC295 camera and processed using Adobe Photoshop. All mouse experiments were overseen by the Garvan Institute of Medical Research/St. Vincent\'s Hospital Animal Ethics Committee.

Positional cloning and genotyping {#s4-3}
---------------------------------

Meiotic recombinants were mapped using polymorphic SSLP and SNP markers to identify a small critical interval on linkage group 20; PCR primers used for mapping are provided in [Table 3](#tbl3){ref-type="table"}. Sequence analysis of candidate genes was performed on cDNA from homozygous wild-type and *ref* mutant embryos.

PCR genotyping was used to identify *ref* mutant embryos following phenotypic analysis. The primer pair 5\'-GTAGGTAAAAGTAAAGCTGGTA-3\' and 5\'-CAAGGGTGTGTTGAACCTGA-3\' amplifies a 136 bp PCR product flanking the e14i15 boundary in the *pdgfra* locus and creates a KpnI restriction site within the wild-type allele, but not within the *ref* mutant allele. Digestion of the wild-type PCR product with KpnI creates fragments of 113 and 23 bp.

Morpholinos and inhibitors {#s4-4}
--------------------------

A *pdgfra* morpholino (5\'-CACTCGCAAATCAGACCCTCCTGAT-3\') was designed to disrupt the splicing of exon 11 and thereby lead to premature truncation of Pdgfra prior to its kinase domain. We injected 12 ng of morpholino at the one-cell stage; this dose did not induce visible toxicity. Furthermore, injection of this morpholino into *ref* mutants did not increase the frequency or severity of their cardiac fusion defects.

For pharmacological inhibition of PDGF signaling ([@bib35]), we incubated embryos in Pdgfr inhibitor V (Calbiochem 521234, Temecula, CA) from the tailbud stage until the 22 somite stage. Three separate experiments were performed, using doses of 0.25--0.4 μM.

In situ hybridization, immunofluorescence, and Alcian blue staining {#s4-5}
-------------------------------------------------------------------

The following probes and antibodies were used: *myl7* (ZDB-GENE-991019--3), *axial/foxa2* (ZDB-GENE-980526--404, *sox17* (ZDB-GENE-991213--1), *hand2* (ZDB-GENE-000511--1)*, pdgfra* (ZDB-GENE-990415--208), *pdgfaa* (ZDB-GENE-030918--2)*, pdgfab* (ZDB-GENE-060929--124)*, pdgfc* (ZDB-GENE-071217--2), anti-GFP (RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798); Abcam ab13970; 1:1000), anti-ZO-1 (RRID:[AB_2533147](https://scicrunch.org/resolver/AB_2533147); Zymed 33--9100; 1:200), and donkey anti-mouse Alexa 488 (RRID:[AB_141607](https://scicrunch.org/resolver/AB_141607); Invitrogen; 1:300). Standard in situ hybridization, fluorescent in situ hybridization, and immunofluorescence were performed using established protocols ([@bib3]; [@bib10]; [@bib78]). Fluorescent in situ hybridization was combined with immunofluorescence as previously described ([@bib79]). Standard in situ hybridization was combined with visualization of transgene expression by creating transverse sections following in situ hybridization, using standard cryoprotection, embedding, and sectioning techniques ([@bib24]) and then performing standard immunofluorescence for GFP on sections. Alcian blue staining was performed as previously described ([@bib36]). Trunks were removed for genotyping prior to Alcian staining.

Images were captured using Zeiss M2Bio, AxioZoom and AxioImager microscopes outfitted with Axiocam cameras and processed with Adobe Photoshop. Confocal stacks were collected using a Leica SP5 confocal laser-scanning microscope and processed using Imaris (Bitplane, Belfast, Ireland).

Timelapse imaging and cell tracking {#s4-6}
-----------------------------------

*Tg(myl7:egfp)* embryos at the 14 somite stage were mounted head down in 0.8% low-melt agarose and placed on a coverslip bottom dish in wells made from a layer of 3% agarose. Timelapse images were collected using a Leica SP5 confocal microscope with a 20X objective, in a chamber heated to 28°C. Confocal stacks of GFP and brightfield images were collected every 4 min for 2--3 hr, starting around the 16 somite stage. In each stack, 30 confocal slices spanning the expression of *Tg(myl7:egfp)* were collected at \~3 μm intervals. Embryos were retained after completion of imaging, and we only analyzed data from embryos that appeared healthy for 24 hr following the timelapse.

Image processing and cell tracking was performed on three-dimensional reconstructions generated with Imaris, using the semi-automated cell tracking module. In each embryo, we tracked 20--30 cells from the two most medial columns of cardiomyocytes on each side. Only tracks in which a cell position could be determined for each timepoint were used for further analysis. We also tracked the tip of the notochord in brightfield images at each timepoint. Although we observed a slight posterior retraction of the notochord over the course of our timelapse analysis, we found that this was the most consistent landmark to use as a reference point to correct for drift that occurred during imaging. Thus, the movement of the tracked notochord tip was subtracted from the movement of each tracked cardiomyocyte. Our wild-type tracking data were largely consistent with our prior studies ([@bib31]), including the velocity of movement, coherence of movement, lack of cell movement in the Z-axis, and direction of wild-type cardiomyocyte trajectories. Subtle differences between these two data sets are likely due to our current use of the notochord as a reference point and the slightly later stage at which we initiated these timelapse experiments.

For quantitative analysis of cardiomyocyte movement, we extracted the X and Y position of each cell at each timepoint along its track, as previously described ([@bib31]). Cell movement properties, including overall speed (distance/time), efficiency (displacement/distance), velocity (displacement/time), and direction, were then calculated for each individual cardiomyocyte. Velocity measurements were split into their X (medial-lateral) and Y (anterior-posterior) components. Cells along the anterior-posterior axis were further divided into top, middle, and bottom subsets, as in our prior work ([@bib31]). Direction was calculated as arctan\[abs(y-displacement)/(x-displacement)\], after aligning movement between the left and right sides. Graphs were made using Matlab (Mathworks, Natick, MA) and Prism (Graphpad, La Jolla, CA) software.

Statistics and replication {#s4-7}
--------------------------

All statistical analyses were performed using a two-tailed unpaired Student's t-test. No statistical methods were used to predetermine sample sizes. Instead, sample sizes were determined based on prior experience with relevant phenotypes and standards within the zebrafish and mouse communities. All results were collected from at least two independent experiments (technical replicates) in which multiple embryos, from multiple independent matings, were analyzed (biological replicates).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"PDGF signaling directs cardiomyocyte movement toward the midline during heart tube assembly\" for consideration by *eLife*. Your article has been favorably evaluated by Marianne Bronner (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This paper from the Yelon lab sheds critical light on early cardiac morphogenesis, namely the movement of the precardiac mesoderm towards the midline. Although it was shown many years ago that the endoderm is important for this process, it has been mostly unclear how it is involved. Starting with a forward genetic screen, the authors identify the role of Pdgf signaling in the process, with the precardiac mesoderm expressing a Pdgf receptor and the endoderm expressing a Pdgf ligand. Further experiments indicate that the Pdgf signaling could be instructive in the movement of the precardiac mesoderm towards the midline. Additional data indicate that Pdgf signaling is also involved in early mouse cardiac development. The paper is very well written and the data of high quality.

Essential revisions:

1\) The concept of paracrine signaling should be further tested by overexpressing *pdgfaa* specifically in the endoderm. In addition, *pdgfc* (another potential ligand for Pdgfra) expression should be analyzed at the relevant stages.

\[The endodermal-myocardial connection should be further developed, also as it is the title of the manuscript.\]

2\) The penetrance of the phenotypes is hard to gauge for both the fish and mouse data. This would be best represented in a table, instead of the figure legends ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 3](#fig3){ref-type="fig"}), where some (but not all) of the data is present. See below:

Fish: The authors must have genotyped all of the embryos, how many of these are \"morphologically evident mutants\"? It is important to provide this information as this may significantly reduce the incidence of the mutants.

Fish, if the authors only see four cardia bifida mutants, and the incidence is also low in the mouse, mention of this phenotype should be removed from the abstract as this is misleading (not the dominant phenotype).

Mouse: can some of the defects in heart development simply be a delay? In the old Grüneberg papers, there is a discussion of embryos being able to catch up.

Mouse: the cardia bifida shown in [Figure 3E-E\'](#fig3){ref-type="fig"} is mild compared to other cardia bifida mutants, is this also accompanied by ventral folding morphogenesis defects and do the embryos develop outside of the yolk sac?

10.7554/eLife.21172.028

Author response

*Essential revisions:*

*1) The concept of paracrine signaling should be further tested by overexpressing pdgfaa specifically in the endoderm. In addition, pdgfc (another potential ligand for Pdgfra) expression should be analyzed at the relevant stages.*

*\[The endodermal-myocardial connection should be further developed, also as it is the title of the manuscript.\]*

We appreciate the reviewers\' interest in our proposed model in which PDGF ligands, produced by the anterior endoderm, signal through the Pdgfra receptor in the ALPM in order to control the directionality of cardiomyocyte behavior. In support of this model, our manuscript shows that *pdgfaa*, encoding one potential ligand for Pdgfra, is expressed in the anterior endoderm ([Figure 7A-P](#fig7){ref-type="fig"}), and the reviewers wonder where other potential ligands for Pdgfra are expressed during the relevant timeframe. In accordance with this suggestion, we have examined the expression of the two other zebrafish genes encoding potential Pdgfra ligands, *pdgfab* and *pdgfc* (Eberhart, et al., 2008, Nat. Genet. 40:290). We found that *pdgfab* is expressed similarly to *pdgfaa* in bilateral medial stripes consistent with the location of the anterior endoderm. However, we did not observe expression of *pdgfc* over background levels in this region. Therefore, it is feasible that both *pdgfaa* and/or *pdgfab* could be produced by the endoderm to signal through Pdgfra in the ALPM. In our revised manuscript, these data are presented in a new figure supplement ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}) and are incorporated into our revised Results section (subsection "The Pdgfra ligand *pdgfaa* is expressed in the anterior endoderm, adjacent to the ALPM", first paragraph).

As another type of evidence in support of our model, our manuscript shows that global overexpression of *pdgfaa* disrupts cardiac fusion ([Figure 7Q--S](#fig7){ref-type="fig"}), suggesting that the spatial restriction of *pdgfa* genes is important for regulating cardiomyocyte movement. The reviewers wonder what would happen if we overexpressed *pdgfaa* specifically in the endoderm: would this have a different effect from that caused by global overexpression? As suggested, we attempted to overexpress *pdgfaa* specifically in the endoderm and evaluate the effects on cardiac fusion. For this purpose, we generated a new transgene, *Tg(sox17:pdgfaa-2A-mCherry)*, in which *pdgfaa* expression is controlled by the endoderm-specific *sox17* promoter (Mizoguchi et al., 2008, *Development***135**:2521). Injection of the *Tg(sox17:pdgfaa-2A-mCherry)* plasmid induced the mosaic expression of *pdgfaa* within the endoderm, as confirmed by examining the colocalization of GFP and mCherry after injection into embryos carrying *Tg(sox17:egfp)* (data not shown). By analyzing expression of the myocardial marker *myl7* at 22 s, we found that injected embryos had significant defects in cardiac fusion, including cardia bifida ([Author response image 1A-D](#fig8){ref-type="fig"}). In addition, the bilateral populations of cardiomyocytes in injected embryos appeared highly dysmorphic and were often accompanied by ectopic *myl7* expression ([Author response image 1A-D](#fig8){ref-type="fig"}). These phenotypes are distinct from those observed in *pdgfra* mutants ([Figure 1C-E](#fig1){ref-type="fig"}) or those induced by global overexpression of *pdgfaa* at the tailbud stage ([Figure 7Q-S](#fig7){ref-type="fig"}). Moreover, these phenotypes suggested that expression of *Tg(sox17:pdgfaa-2A-mCherry)* might disrupt the formation of the ALPM in the early gastrula. Indeed, we found that embryos injected with *Tg(sox17:pdgfaa-2A-mCherry)* displayed dysmorphic and ectopic expression of the ALPM marker *hand2* at 6 s ([Author response image 1E-H](#fig8){ref-type="fig"}). In addition, we found that embryos with particularly high mosaicism of *Tg(sox17:pdgfaa-2A-mCherry)* exhibited morphologically evident gastrulation defects (data not shown). These early defects in gastrulation and ALPM formation correspond with the early expression of *sox17,* which initiates in endoderm cells during gastrulation (Kikuchi et al., 2000, *Genes Dev.***14**:1279). These results are also consistent with previous studies in frog and chick that have shown a role for PDGF signaling in regulating mesoderm movement during gastrulation (Nagel et al., 2004, *Development***131**:2727; Yang et al., 2008, *Development***135**:3521; Damm et al., 2011, *Development***138**:565).10.7554/eLife.21172.026Author response image 1.Mosaic expression of *pdgfaa* in the endoderm causes defects in cardiac fusion and ALPM formation.(**A-D**) Lateral (**A**, **B**) and dorsal (**C**, **D**) views depict the expression of *myl7* at 22 s in a representative uninjected embryo (wt; **A**, **C**) and in a representative embryo injected with *Tg(sox17:pdgfaa-2A-mCherry)* plasmid (injected; **B**, **D**). Injected embryos exhibited a range of cardiac fusion phenotypes: cardia bifida with disrupted morphology (**B**, **D**; n=6/14), fusion only in posterior positions (not shown; n=3/14), or normal fusion (n=5/14). (**E-H**) Lateral (**E**, **F**) and dorsal (**G**, **H**) views depict the expression of *hand2* at 6 s in a representative uninjected embryo (wt; **E**, **G**) and in a representative embryo injected with *Tg(sox17:pdgfaa-2A-mCherry)* plasmid (injected; **F**, **H**). Instead of being confined to narrow bilateral stripes of ALPM as in wt (**E**, **G**), *hand2* was expressed ectopically in some injected embryos (F, H; n=2/11) or expressed in a dysmorphic ALPM (not shown; n=5/11). Normal *hand2* expression was observed in a few injected embryos (n=4/11). Scale bars: 60 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.21172.026](10.7554/eLife.21172.026)

Unfortunately, the early defects caused by expression of *Tg(sox17:pdgfaa-2A-mCherry)* preclude the assessment of cardiac fusion in this context. If gastrulation and ALPM formation are abnormal, we cannot effectively evaluate the subsequent progression of cardiomyocyte movement toward the midline. In future studies, we plan to develop more sophisticated tools to control the expression of *pdgfaa* both temporally and spatially. For example, we plan to construct new transgenes and new stable lines employing the HOTcre system (Hesselson et al., 2009, *PNAS***106**:14896) in order to regulate *pdgfaa* expression in the endoderm after gastrulation is complete. Ideally, we aim to generate the appropriate strains for the conditional inactivation of *pdgfaa, pdgfab*, and *pdgfra* in a tissue-specific and temporally-controlled manner, since this would be a particularly effective way to test whether PDGF ligands produced by the endoderm signal through Pdgfra in the ALPM in order to influence the direction of myocardial movement. We have incorporated this idea into our revised Discussion section (first paragraph). Since the development of the necessary tools for these experiments will require more time than is appropriate for a standard revision, we view this as a separate body of work that lies beyond the scope of our current manuscript.

We hope that these modifications to our manuscript will satisfy the reviewers\' interest in further development of the endoderm-myocardium connection. We note that the reviewers commented that this connection \"is the title of our manuscript\". We presume that they meant to point out that we mention this connection in our Abstract, since our title did not include any reference to the endoderm.

*2) The penetrance of the phenotypes is hard to gauge for both the fish and mouse data. This would be best represented in a table, instead of the figure legends ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 3](#fig3){ref-type="fig"}), where some (but not all) of the data is present. See below:*

Fish: The authors must have genotyped all of the embryos, how many of these are \"morphologically evident mutants\"? It is important to provide this information as this may significantly reduce the incidence of the mutants.

Fish, if the authors only see four cardia bifida mutants, and the incidence is also low in the mouse, mention of this phenotype should be removed from the abstract as this is misleading (not the dominant phenotype).

Mouse: can some of the defects in heart development simply be a delay? In the old Grüneberg papers, there is a discussion of embryos being able to catch up.

*Mouse: the cardia bifida shown in [Figure 3E-E](#fig3){ref-type="fig"}\' is mild compared to other cardia bifida mutants, is this also accompanied by ventral folding morphogenesis defects and do the embryos develop outside of the yolk sac?*

The cardiac phenotypes in *pdgfra* mutant zebrafish and *Pdgfra* mutant mice are incompletely penetrant and have variable expressivity. As suggested by the reviewers, we have added four new tables to our revised manuscript to clarify these points ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}, and [Table 5](#tbl5){ref-type="table"}). We have also adapted our revised text (Results) and figure legends ([Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}; [Figure 3](#fig3){ref-type="fig"}) to accommodate the incorporation of these new tables. The data presented in [Table 2](#tbl2){ref-type="table"} illustrate the frequency with which we typically observed morphologically evident cardiac phenotypes in zebrafish *ref* mutants: that is, the penetrance of the *ref* mutant phenotype appeared higher when we examined embryos at earlier stages (approximately 75% penetrance at 20 s) than it did at later stages (approximately 44% penetrance at 48 hpf). These data suggest that some *ref* mutants recover as development proceeds, and we have added this point to our revised text ([Figure 1](#fig1){ref-type="fig"} legend). Finally, as suggested by the reviewers and in accordance with the data shown in our new tables, we have removed mention of cardia bifida from the Abstract.

We have also revised our text to address the reviewers\' questions about the cardiac defects observed in *Pdgfra* mutant mice. We agree with the reviewers that developmental delay is an important consideration when evaluating cardiac phenotypes. However, the severe cardiac defects that we observed in *Pdgfra* mutants ([Figure 3C-E\'](#fig3){ref-type="fig"}) are not likely to be a result of general developmental delay, as these mutant phenotypes do not resemble wild-type cardiac morphology at younger stages. We had included this point in our original manuscript within the legend to [Figure 3](#fig3){ref-type="fig"}; to highlight it more effectively, we moved this information into our revised Results section (subsection "Mutation of *Pdgfra* disrupts heart tube assembly in mice", last paragraph). The reviewers also wondered whether the cardia bifida that we observed was accompanied by ventral folding morphogenesis defects or by development outside of the yolk sac. We did not observe these features, and we have incorporated this information into our revised Results section (see aforementioned subsection).

[^1]: ^∗^ Tabulated from 15 embryos with morphologically evident phenotypes from clutch depicted in [Figure 1C--E](#fig1){ref-type="fig"} and in [Table 2](#tbl2){ref-type="table"}. See [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} for additional data.

[^2]: ^†^ Tabulated from 454 embryos with morphologically evident phenotypes collected from multiple clutches. See [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} for representative images.

[^3]: ^∗^ NG=not genotyped.

[^4]: ^†^ Calculated with the assumption that 25% of embryos are -/-.

[^5]: ^∗^ No observed phenotype.

[^6]: ^†^ See [Table 5](#tbl5){ref-type="table"} for detail on observed phenotypes.

[^7]: ^‡^ Chi-squared test p\<0.05 compared to expected.
